Breaking News
FONT-SIZE Plus   Neg
Share SHARE

UCB Says FDA Okays Neupro For Parkinson's Disease, Restless Legs Syndrome

RELATED NEWS
Trade UCB now with 

Biopharmaceutical firm UCB SA (UCB: Quote) on Tuesday said the U.S. Food and Drug Administration approved Neupro (Rotigotine Transdermal System) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's disease, or PD, and as a treatment for moderate-to-severe primary Restless Legs Syndrome, or RLS.

Neupro is a dopamine agonist patch that provides continuous drug delivery for patients with PD and RLS. It was previously approved by the FDA for the signs and symptoms of early stage idiopathic PD. The FDA has also approved UCB's new formulation of Neupro.

William Ondo, Professor, Department of Neurology, University of Texas Health Science Center, said, "RLS can be a serious condition with symptoms that affect patients during the day as well as at night; and Parkinson's disease symptoms can have a broad impact on patients. Neupro provides a novel way of treating RLS and PD through continuous transdermal dopaminergic delivery. It can help patients manage the unpredictable nature of these chronic conditions."

The effectiveness of Neupro in treating the signs and symptoms of idiopathic PD was established in five parallel group, randomized, double-blind placebo-controlled trials. Patients underwent a weekly titration of Neupro in 2 mg/24 hours increments to either the randomized dose or optimal dose.

In three trials, statistically significant improvements in the combined scores on the Unified Parkinson's Disease Rating Scale, or UPDRS, were observed in early stage PD patients receiving Neupro compared with patients receiving placebo.

Two trials of Neupro in patients with advanced PD examined change from baseline during so called off times or periods when the effectiveness of medication wears off and PD symptoms return. Statistically significant changes in off times were observed in advanced PD patients receiving Neupro compared with those who received placebo.

The efficacy of Neupro in the treatment of RLS was primarily evaluated in two fixed-dose, randomized, double-blind, placebo-controlled trials with six-month maintenance periods. Patients received Neupro doses ranging from 0.5 mg/24 hours to 3 mg/24 hours, or placebo, once daily.

Statistically significant improvements in sum scores on the International RLS Rating Scale and the Clinical Global Impression - Improvement assessment were observed in RLS patients receiving Neupro compared with those receiving placebo.

The precise mechanism of action of Neupro as a treatment for these diseases is unknown. As a PD treatment, Neupro's action is thought to be related to its ability to stimulate dopamine receptors within the caudate-putamen, the region of the brain that regulates movement.

In RLS, the mechanism of action of Neupro may be related to its ability to stimulate dopamine receptors.

Neupro will be available in U.S. retail pharmacies in July.

The stock closed in Brussels on Monday higher by 4.57 percent at 33.83 euros on a volume of 587,010 shares.

Register
To receive FREE breaking news email alerts for UCB SA and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.